07:00 , Sep 2, 2013 |  BC Week In Review  |  Clinical News

XM-ONE regulatory update

Allenex said Mexico approved XM-ONE to detect human leukocyte antigen (HLA) and non-HLA antibodies between donor and recipient in organ transplantations. Allenex immediately launched XM-ONE in Mexico. Allenex's AbSorber AB subsidiary already markets XM-ONE...
08:00 , Feb 11, 2013 |  BC Week In Review  |  Company News

Allenex transplant, diagnostic news

Allenex received €215,000 ($292,293) as part of a €2.6 million ($3.6 million) award from the EU's Seventh Framework Program (FP7) to the EUROSTAM consortium of European Transplant Centers, which aims to enhance transplantation in patients...
07:00 , Aug 6, 2012 |  BioCentury  |  Emerging Company Profile

Milo: Dismissing dystrophin

Milo Biotechnology LLC is developing a gene therapy to treat muscular dystrophy that up-regulates follistatin, a protein already present in the body, which could avoid immune reactions that have scuttled previous gene therapies. The company's only...
07:00 , Jun 4, 2012 |  BC Week In Review  |  Clinical News

XM-ONE: Postmarketing study started

Allenex (formerly LinkMed AB) said Tulane University's Tulane Medical Center began an investigator-sponsored, prospective trial to evaluate XM-ONE before and 6 months after transplantation in about 100 kidney transplant patients. Allenex's AbSorber AB subsidiary already...
08:00 , Feb 13, 2012 |  BioCentury  |  Emerging Company Profile

Halo: Treating DMD symptoms

Most companies developing therapeutics for Duchenne muscular dystrophy are targeting the genetic defects that cause the disease. Halo Therapeutics LLC, a company funded by two patient groups, thinks there is still room for treatments to...
07:00 , May 30, 2011 |  BC Week In Review  |  Company News

LinkMed AB management update

LinkMed AB (SSE:LMED), Stockholm, Sweden   Business: Finance   Departed: Founder Ingemar Lagerlof as CEO; he is succeeded by Anders Karlsson, formerly CEO of LinkMed's AbSorber AB subsidiary   ...
07:00 , Apr 25, 2011 |  BC Week In Review  |  Company News

LinkMed AB transplant news

LinkMed's board announced plans to change its name to Allenex AB following its decision last year to shift its investment focus to the transplant sector. The change will be proposed at a May 10...
07:00 , Sep 13, 2010 |  BC Week In Review  |  Company News

LinkMed transplant news

Private equity company LinkMed announced plans to shift its investment focus to the transplant sector. LinkMed said it will also focus on developing existing and new products from its AbSorber AB subsidiary, including an AB0...
08:00 , Nov 16, 2009 |  BC Week In Review  |  Company News

AbSorber AB, LinkMed AB deal

Private equity company LinkMed will increase its holding in AbSorber to 93.8% from 43%. LinkMed will acquire 40.9% of AbSorber from Koncentra Holding AB for SEK58 ($8.4 million) and the remaining 9.9% from AbSorber founder...
07:00 , Mar 9, 2009 |  BC Week In Review  |  Clinical News

XM-ONE diagnostic data

Researchers from Johns Hopkins University School of Medicine and colleagues published in Transplantation data from a 2-year study that showed 16 (46%) of 35 patients who tested positive for donor-reactive AECA with the XM-ONE test...